Ekin Kadioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekin Kadioglu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cantürk Taşçı
Division of Pulmonology, Gulhane Faculty of Medicine & Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey
2 shared publications - Deniz Doğan
UNIVERSITY OF HEALTH SCIENCES, GÜLHANE SCHOOL OF MEDICINE, GÜLHANE MEDICINE PR. (ANKARA)
2 shared publications - Gonca Fidan
UNIVERSITY OF HEALTH SCIENCES, GÜLHANE SCHOOL OF MEDICINE, GÜLHANE MEDICINE PR. (ANKARA)
2 shared publications - Gülden Yılmaz
Gülhane Training and Research Hospital, University of Health Sciences
2 shared publications - Nesrin Öcal
Department of Pulmonary Medicine, University of Health Sciences Gulhane School of Medicine Ankara, Türkiye
2 shared publications - Sümeyye Köşger
Health Sciences University, Gulhane Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkiye
2 shared publications
Latest Publications
- 14 June 2021
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 26 (2) , 257-266
COVID-19 Pandemisinde Üçüncü Basamak Bir Hastane Deneyimi
- 14 June 2021
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 26 (2) , 257-266
COVID-19 Pandemisinde Üçüncü Basamak Bir Hastane Deneyimi
- Open Access
- 9 June 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (9) , e14461
The boundaries between survival and nonsurvival at COVID‐19: Experience of tertiary care pandemic hospital
Objective Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients. Methods In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated. Results The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002). Conclusion It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.
- 9 June 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (9) , e14461
Open AccessThe boundaries between survival and nonsurvival at COVID‐19: Experience of tertiary care pandemic hospital
Objective Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients. Methods In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated. Results The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002). Conclusion It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.